ClinConnect ClinConnect Logo
Search / Trial NCT01893710

International (Pediatric) Peritoneal Biobank

Launched by HEIDELBERG UNIVERSITY · Jul 2, 2013

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Peritoneal Dialysis Parietal Peritoneum Omentum Chronic Kidney Disease Vasculopathy

ClinConnect Summary

The International Pediatric Peritoneal Biobank trial is studying changes in the peritoneal membrane, which is important for children undergoing peritoneal dialysis (PD) due to kidney failure. This trial aims to collect tissue samples from children on PD to understand how their bodies react to the treatment and how these changes might affect their health. The researchers will gather these samples during routine medical procedures, like inserting a PD catheter or during surgeries, ensuring that the process is safe and does not significantly increase the risk of surgery.

To participate in this study, children and adults between the ages of 0 and 90 who are on PD or undergoing certain elective abdominal surgeries may be eligible. Participants will need to provide consent, and for younger patients, their parents or guardians will need to agree as well. By joining this trial, participants can help researchers learn more about the effects of PD on the body, which may lead to better treatment options in the future. This study is currently recruiting participants and is focused on understanding both the immediate and long-term impacts of PD on children’s health.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Age 0 to 90 years
  • CKD 5D, peritoneal dialysis and
  • Patients with normal renal function and elective abdominal surgery due to limited abdominal pathology (such as hernia repair, gallstones....)
  • Patients post PD and post Tx
  • Oral and written consent
  • Ability to consent of the adult patient and of the parents and legal guardian of patients not yet of legal age, respectively
  • Exclusion Criteria:
  • Abdominal adhesions, malformation and inflammation beyond PD induced changes
  • Patients with disseminated tumour disease
  • Patients with critical heart failure and other medical conditions, where the additional procedure may confer an increased increase risk
  • Pregnancy
  • Preterm babies (below 37 weeks of gestational age)
  • Serum hemoglobin \< 10 g/dl in newborns and \< 8 g/dl in children and adults

About Heidelberg University

Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.

Locations

Kansas City, Missouri, United States

Birmingham, Alabama, United States

Stockholm, , Sweden

Essen, , Germany

Strasbourg, , France

Narberth, Pennsylvania, United States

Vienna, , Austria

Ghent, , Belgium

Prague, , Czechia

Lyon, , France

Heidelberg, Bw, Germany

Berlin, , Germany

Cologne, , Germany

Hamburg, , Germany

Marburg, , Germany

Budapest, , Hungary

Genova, , Italy

Milano, , Italy

Padova, , Italy

Vilnius, , Lithuania

Kuala Lumpur, , Malaysia

Krakow, , Poland

Barcelona, , Spain

Bern, , Switzerland

Adana, , Turkey

Istanbul, , Turkey

Patients applied

0 patients applied

Trial Officials

Claus P Schmitt, MD

Principal Investigator

University of Heidelberg, Center for Pediatric and Adolescent Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials